The Phase 3 SURPASS-PEDS trial found tirzepatide improved glycemic control and weight outcomes in youth-onset type 2 diabetes, with benefits lasting one year.
Most youth with type 1 diabetes in sub-Saharan Africa lack autoimmune markers, suggesting a distinct, non-autoimmune form of insulin-deficient diabetes.
A 40-year study found that higher third-trimester glucose levels in insulin-dependent pregnancies were tied to increased obesity risk in adult offspring.